alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                    GLOBAL INTELLICOM, INC. AND SUBSIDIARIES

                                   EXHIBIT 11

                     COMPUTATION OF INCOME PER COMMON SHARE

<TABLE>
<CAPTION>
                                                                YEARS ENDED DECEMBER 31,
                                                       -----------------------------------------
                                                          1997             1996           1995
                                                       -----------     -----------    ----------
<S>                                                    <C>             <C>            <C>  
BASIC INCOME PER COMMON SHARE

INCOME:

   Income (loss) from continuing operations            $(2,302,808)    $  (706,493)   $   203,332

   Less: Dividends                                         188,673              --            --

   Less: Cumulative undeclared dividend
     on Series 3 Convertible Preferred Stock                61,250          61,250            --
                                                       ------------    -----------    -----------

   Adjusted income (loss) from continuing operations   $(2,552,731)   $  (767,743)    $   203,332
                                                       ------------   ------------    -----------
                                                       ------------   ------------    -----------

   Discontinued operations                             $(7,133,152)   $  (378,895)    $    66,851
                                                       ------------   ------------    -----------
                                                       ------------   ------------    -----------

SHARES:

   Weighted average number of common
     shares outstanding                                  7,481,307      3,527,053       2,927,170
                                                       ------------   ------------    -----------
                                                       ------------   ------------    -----------

BASIC INCOME (LOSS) PER COMMON SHARE:
   Income (loss) from continuing operations             $     (.34)    $     (.22)     $      .07
   Discontinued operations                                    (.95)          (.11)            .02
                                                       ------------   ------------    -----------
                                                       $     (1.29)    $     (.33)     $      .09
                                                       ------------   ------------    -----------
                                                       ------------   ------------    -----------
</TABLE>
[No. 16435-7-III.

Division Three.

December 30, 1997.]

#### *In the Matter of the Marriage of*Marvel Allen, *Appellant,*and Patrick J. Zlateff, *Respondent.*

Appeal from a judgment of the Superior Court for Benton County, No. 80-3-00342-0, Dennis D. Yule, J., entered January 28, 1997. *Reversed*by unpublished opinion per Schultheis, A.C.J., concurred in by Kurtz and Brown, JJ.
#### UNITED STATES of America, Plaintiff-Appellant, v. John Gilbert OGLES, Defendant-Appellee. United States of America, Plaintiff-Appellee, v. John Gilbert Ogles, Defendant-Appellant.

Nos. 03-10439, 04-10069.

United States Court of Appeals, Ninth Circuit.

Nov. 16, 2005.

Maria Davila, Esq., USTU-Office of the U.S. Attorney Evo A. Deconcini, Tucson, AZ, Michael Rotker, U.S. Department of Justice, Washington, DC, for Plaintiff-Appellant.

Richard E. Gardiner, Fairfax, VA, for Defendant-Appellee.

Before SCHROEDER, Chief Judge.

*1222ORDER

Upon the vote of a majority of nonre-cused regular active judges of this court, it is ordered that this case be reheard by the en banc court pursuant to Circuit Rule 35-3. The three-judge panel opinion shall not be cited as precedent by or to this court or any district court of the Ninth Circuit, except to the extent adopted by the en banc court.
#### § 1313.34 Disposition of the international transaction declaration.

The broker or trader must retain an official record of the declaration (DEA Form 486) (available from the DEA Diversion Control Division secure network application after the Administration issues a transaction identification number) as the official record of the international transaction. In accordance with part 1310 of this chapter, declarations involving listed chemicals must be retained for two years.

[81 FR 97040, Dec. 30, 2016]
LOG OF MEETING

DIRECTORATE FOR ENGINEERING SCIENCES

SUBJECT: ASTM Juvenile Products Subcommittee Meetings

DATE OF MEETING: June 27, 2013

PLACE OF MEETING: ASTM Headquarters

LOG ENTRY SOURCE: Patricia Edwards

COMMISSION ATTENDEES: Patricia Edwards, Jonathan Midgett, Suad 

Wanna-Nakamura, Rick McCallion, etc. 

NON-COMMISSION ATTENDEES: Contact ASTM for attendee list

SUMMARY OF MEETING:

Hand Held Carriers –

Two ballot items (restraints warning label and hook specs) have been approved but not 

yet included in the standard for publication. These items will be processed and a new 

version will be approved on July 1st, publication expected by the end of July. 

Auto-locking Test Task Group Report:

A draft ballot item to revise this test procedure was shared with the sub-committee. The 

ballot item was drafted by the task group as a result of the testing performed in April at 

SGS Laboratories. This ballot item is expected be sent out to ballot in the next few days.

The sub-committee discussed various aspects of the ballot item, suggested editorial edits 

were made. 

Inclined Sleep Products

The following task groups provided reports. And the draft standard was edited in 

response to some of the reports. Many of the task groups are not yet done with the work 

needed to finalize the draft standard. 

1) Freestanding newborn inclined sleep product 

2) Unintentionally folding requirement 

3) Side height for newborn 

4) Newborn seat back length test method 

5) Scope 

6) Definitions 

7) Warnings 
Bassinets –

An announcement was made that two ballot items will be sent out next week. These items 

were not reviewed or discussed at the meeting. 

CPSC staff provided a rulemaking update, outlining the staff recommendations that were 

included in the final rulemaking briefing package. 

Stroller Meeting –

Pinch Point 2D strollers task group provided a report. Discussion included refinements 

and edits to the last draft. 

Effective date differences between the NPR and JPMA was raised. The possibility of 

aligning the dates was discussed and will be pursued by JPMA. 

Rockers –

The draft forward stability test was reviewed and changes were suggested and discussed. 

A change to scope, to clarify multi-mode products, was discussed. It was decided to add 

wording similar to what was added for the inclined sleeper standard. 

Other recommended changes in the standard were reviewed. These changes were not 

included in the agenda handout.
<PAGE>   1

                                                                    EXHIBIT 23.3

               CONSENT OF ERNST & YOUNG(CIS) LTD., INDEPENDENT AUDITORS

We consent to the incorporation by reference, in the Registration Statements
(Forms S-8 No. 333-45669 and No. 333-47573), of our report dated February 16,
1998 except for Note 12, as to which the date is November 12, 1998 (EDN
Sovintel), with respect to the financial statements and schedules of Global
TeleSystems Group, Inc. included in Amendment No. 1 to the Company's Annual
Report on Form 10-K/A for the year ended December 31, 1997.

                                        Ernst & Young(CIS) Ltd.

Moscow, Russia
December 4, 1998
§ 520.1484 Neomycin. ( a ) *Specifications.* ( 1 ) Each ounce of powder contains 20.3 grams (g) neomycin sulfate (equivalent to 14.2 g neomycin base).
( 2 ) Each milliliter of solution contains 200 milligrams (mg) neomycin sulfate (equivalent to 140 mg neomycin base).
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (e) of this section. ( 1 ) No. 054771 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section.
( 2 ) Nos. 016592, 054771, 058005, and 061133 for use of product described in paragraph (a)(1) as in paragraphs (e)(1) and (e)(2) of this section.
( 3 ) Nos. 016592, 054771, and 058005 for use of product described in paragraph (a)(2) as in paragraph (e)(1) of this section.
( c ) *Related tolerances.* See § 556.430 of this chapter.
( d ) *Special labeling considerations.* Labeling shall bear the following warning statements: “A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. Use of more than one product containing neomycin or failure to follow withdrawal times may result in illegal drug residues.”
( e ) *Conditions of use* — ( 1 ) *Cattle, swine, sheep, and goats* — ( i ) *Amount.* 10 mg per pound (/lb) of body weight per day (22 mg per kilogram (/kg)) in divided doses for a maximum of 14 days.
( ii ) *Indications for use.* For the treatment and control of colibacillosis (bacterial enteritis) caused by *Escherichia coli* susceptible to neomycin sulfate.
( iii ) *Limitations.* Discontinue treatment prior to slaughter as follows: Cattle, 1 day; sheep, 2 days; swine and goats, 3 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Turkeys* — ( i ) *Amount.* 10 mg/lb of body weight per day (22 mg/kg) for 5 days.
( ii ) *Indications for use.* For the control of mortality associated with *E. coli* susceptible to neomycin sulfate in growing turkeys.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 56866, Sept. 28, 2006, as amended at 71 FR 68738, Nov. 28, 2006; 78 FR 17596, Mar. 22, 2013; 78 FR 28825, May 20, 2014; 81 FR 22523, Apr. 18, 2016; 81 FR 94989, Dec. 27, 2016; 84 FR 8973, Mar. 13, 2019; 88 FR 55563, Aug. 16, 2023; 88 FR 84700, Dec. 6, 2023]
#### § 331.21 Test modifications.

The formulation or mode of administration of certain products may require a modification of the United States Pharmacopeia 23/National Formulary 18 acid neutralizing capacity test. Any proposed modification and the data to support it shall be submitted as a petition under the rules established in § 10.30 of this chapter. All information submitted will be subject to the disclosure rules in part 20 of this chapter.

[61 FR 4823, Feb. 8, 1996]
§ 1.1425 What must be included in a petition requesting a waiver for a type of entity? In addition to meeting the requirements on the content and format of a citizen petition in § 10.30 of this chapter, a petition requesting a waiver for a type of entity must: ( a ) Specify the type of entity to which the waiver would apply and the requirements of this subpart to which the waiver would apply;
( b ) Present information demonstrating why application of the requirements requested to be waived would result in an economic hardship for the type of entity, including information about the unique circumstances faced by the type of entity that result in unusual economic hardship from the application of these requirements;
( c ) Present information demonstrating why the waiver will not significantly impair FDA's ability to rapidly and effectively identify recipients of a food to prevent or mitigate a foodborne illness outbreak or to address credible threats of serious adverse health consequences or death to humans or animals as a result of such food being adulterated under section 402 of the Federal Food, Drug, and Cosmetic Act or misbranded under section 403(w) of the Federal Food, Drug, and Cosmetic Act; and
( d ) Present information demonstrating why the waiver would not otherwise be contrary to the public interest.
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

Y.A., a child

,

Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 18

- 3623

[ February 6, 2020 ]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm

Beach County ; James L. Martz , Judge; L.T. Case No.

502017CJ003316XXXXMB

.

Carey Haughwout, Public Defender, and Patrick B. Burke, Assistant

Public Defender, West Palm Beach, for appellant.

Ashley Moody, Attorney General, Tallahassee, and Deborah Koenig,

Assistant Attor ney General, West Palm Beach, for appellee.

P ER C URIAM

.

Affirmed.

C IKLIN

, C ONNER and K UNTZ , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
#### § 516.119 Permanent-resident U.S. agent for foreign requestors and holders.

Every foreign requestor and holder shall name a permanent resident of the United States as their agent upon whom service of all processes, notices, orders, decisions, requirements, and other communications may be made on behalf of the requestor or holder. Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes. The permanent resident U.S. agent may be an individual, firm, or domestic corporation and may represent any number of requestors or holders. The name and address of the permanent-resident U.S. agent shall be submitted to the Director, OMUMS, and included in the index file.
# Fourth Court of Appeals
San Antonio, Texas

January 10, 2017

No. 04

- 16

- 00812

- CR

Gary ALVAREZ, Appellant

v.

The STATE of Texas, Appellee

From the 227th Judicial District Court, Bexar County, Texas

Trial Court No. 2016CR4637B Honorable Kevin M. O'Connell, Judge Presiding



### O R D E R

Gary Alvarez entered into a plea bargain with the State, pursuant to which he pleaded
nolo contendere to the charge of injury to a child

. The trial court imposed sentence in accordance with the agreement and signed a certificate stating this “ is a plea

- bargain case, and the defendant has NO right of appeal. ” See T EX

. R. A PP

. P. 25.2(a)(2). Alvarez timely filed a notice of appeal. The clerk ’ s record, which includes the trial court ’ s r ule 25.2(a)(2) certification and a written plea bargain agreement, has been filed. See T EX

. R. A PP

. P. 25.2(d). This court must dismiss an appeal “ if a certification that shows the defendant has the right of appe al has not been made part of the record. ” Id

.

The clerk ’ s record establishes the punishment assessed by the court does not exceed the punishment recommended by the prosecutor and agreed to by the defendant. See T EX

. R. A PP

. P. 25.2(a)(2). The record also appears to support the trial court ’ s certification that Alvarez does not have a right to appeal. See Dears v. State , 154 S.W.3d 610 (Tex. Crim. App. 2005) (holding that court of appeals should review clerk ’ s record to determine whether trial court ’ s certi fication is accurate).

Alvarez is hereby given notice that this appeal will be dismissed pursuant to r ule 25.2(d) of the Texas Rules of Appellate Procedure unless an amended certification showing that he has the right to appeal is made part of the appell ate record by January 31, 2017

. See T EX

. R. A PP

. P. 25.2(d); Daniels v. State , 110 S.W.3d 174 (Tex. App.

— San Antonio 2003, order), disp. on merits, No. 04

- 03

- 00176

- CR, 2003 WL 21508347 (July 2, 2003, pet. ref ’ d) (not designated for publication).We order all appellate deadlines suspended until further order of the court. We further

order the clerk of this court to serve copies of this order on the attorneys of record and the court reporter

.

__________________ _______________ Luz Elena D. Chapa, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said
court on this 10th day of January, 2017

.

_____________ ______________________ Keith E. Hottle
Clerk of Court
<PAGE>   1
                                                                    EXHIBIT 23.2





                         CONSENT OF INDEPENDENT AUDITORS





The Board of Directors and Stockholders
Telewest Communications plc


We consent to the incorporation by reference in the Registration Statements
(Nos. 333-16021 and 333-16023) on Form S-8 of Tele-Communications International,
Inc. of our report dated March 19, 1998, relating to the consolidated balance
sheet of Telewest Communications plc and subsidiaries as of December 31, 1997
and 1996, and the related consolidated statements of operations and cash flows
for each of the years in the three-year period ended December 31, 1997, which
report appears in the December 31, 1997 annual report on Form 10-K of
Tele-Communications International, Inc.






KPMG Audit Plc
Chartered Accountants
Registered Auditors
London, England


March 23, 1998
I 

118TH CONGRESS 

2D SESSION H. R. 7230 

To amend the definition of extremely low-income families under the United 

States Housing Act of 1937. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 5, 2024 

Mrs. GONZA ́LEZ-COLO ́N (for herself and Mr. TORRES of New York) introduced 

the following bill; which was referred to the Committee on Financial Services 

A BILL 

To amend the definition of extremely low-income families 

under the United States Housing Act of 1937. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Puerto Rico Low-In5 come Housing Support Act’’. 

6 SEC. 2. DEFINITION OF EXTREMELY LOW-INCOME FAMI7 LIES. 

8 Clause (i) of section 3(b)(2)(C) of the United States 

9 Housing Act of 1937 (42 U.S.C. 1437a(b)(2)(C)(i)) is 

10 amended— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7230 IH

1 (1) by striking ‘‘Puerto Rico or any other’’ and 

2 inserting ‘‘any’’; and 

3 (2) by inserting before the closing parentheses 

4 the following: ‘‘other than Puerto Rico and in the 

5 case of public housing agencies and projects located 

6 in Puerto Rico, the same poverty guidelines as used 

7 for the contiguous 48 States and the District of Co8 lumbia shall apply’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1229 Calcium stearate. ( a ) Calcium stearate (Ca(C17H35COO)2, CAS Reg. No. 1529-23-0) is the calcium salt of stearic acid derived from edible sources. It is prepared as a white precipitate by mixing calcium chloride and sodium stearate in aqueous solution.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 64, which is incorporated by reference, and the requirements of § 172.860(b)(2) of this chapter. Copies of the Food Chemicals Codex are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter; a lubricant and release agent as defined in § 170.3(o)(18) of this chapter; and a stabilizer and thickener as defined in § 170.3(o)(28) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52445, Nov. 18, 1983]
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                                            <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JUL-01-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                         9,295,048
<SECURITIES>                                   0
<RECEIVABLES>                                  726,357
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               10,021,405
<PP&E>                                         7,915,431
<DEPRECIATION>                                 (5,818,684)
<TOTAL-ASSETS>                                 14,559,920
<CURRENT-LIABILITIES>                          2,267,810
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     12,292,110
<TOTAL-LIABILITY-AND-EQUITY>                   14,559,920
<SALES>                                        0
<TOTAL-REVENUES>                               (847,886)
<CGS>                                          0
<TOTAL-COSTS>                                  121,460
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                (969,346)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (969,346)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (969,346)
<EPS-BASIC>                                    (.59)
<EPS-DILUTED>                                  0



</TABLE>
Exhibit 99.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of Novex Systems International, Inc. on
Form 10-KSB for the period ended May 31, 2002, as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Daniel W. Dowe, the
President and Acting Treasurer of the Company, certify, pursuant to 18 U.S.C.
ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002,
that:

      (1)   The Report fully complies with the requirements of section 13(a) and
            15(d) of the Securities and Exchange Act of 1934; and

      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and result of operations
            of the Company.

/s/ Daniel W. Dowe


Daniel W. Dowe
President and Acting Treasurer
#### § 500.90 Waiver of requirements.

In response to a petition or on the Commissioner's own initiative, the Commissioner may waive, in whole or in part, the requirements of this subpart except those provided under § 500.88. A petition for this waiver may be filed by any person who would be adversely affected by the application of the requirements to a particular compound. The petition shall explain and document why the requirements from which a waiver is requested are not reasonably applicable to the compound, and set forth clearly the reasons why the alternative procedures will provide the basis for concluding that approval of the compound satisfies the requirements of the anticancer provisions of the act. If the Commissioner determines that waiver of any of the requirements of this subpart is appropriate, the Commissioner will state the basis for that determination in the regulation approving marketing of the sponsored compound.

(Approved by the Office of Management and Budget under control number 0910-0228)